Boehringer/WellPoint Outcomes Research To Inform Pradaxa Treatment
The study in non-valvular atrial fibrillation patients is the first project to launch under a five-year research agreement between Boehringer Ingelheim and WellPoint.
The study in non-valvular atrial fibrillation patients is the first project to launch under a five-year research agreement between Boehringer Ingelheim and WellPoint.